Drug Discovery for Mitochondrial Disorders

NRG Therapeutics is dedicated to developing innovative treatments for neurodegenerative diseases, particularly focusing on restoring mitochondrial function to combat conditions like Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). The company is advancing a pipeline of small molecule inhibitors targeting the mitochondrial permeability transition pore (mPTP), which plays a critical role in the pathology of these diseases. By inhibiting the mPTP, NRG Therapeutics aims to prevent the toxic effects of misfolded proteins such as α-synuclein and TDP-43, which are known to contribute to neuronal degeneration. Their lead candidate, NRG5051, is designed to be orally bioavailable and capable of penetrating the brain, offering a promising approach to mitigate mitochondrial dysfunction and its associated neuroinflammation.

The scientific foundation of NRG Therapeutics is rooted in cutting-edge research in mitochondrial biology, enabling the identification of novel therapeutic targets for neurodegenerative disorders. The company’s pre-clinical pipeline includes a series of structurally differentiated mPTP inhibitors that have shown potential as first-in-class treatments. NRG5051 has demonstrated neuroprotective effects in pre-clinical models, and the company has secured funding from The Michael J. Fox Foundation to support its development. This funding will facilitate essential studies to advance NRG5051 into human clinical trials, with the ultimate goal of partnering with leading pharmaceutical companies for further clinical development and commercialization.

United Kingdom

NRG Therapeutics is passionate about bringing new medicines and hope to the growing number of people worldwide living with debilitating neurodegenerative diseases. The company is an innovative neuroscience company targeting mitochondrial dysfunction for the treatment of neurodegenerative diseases such as Parkinson's and ALS. NRG Therapeutics has been awarded a $500K grant from The Michael J. Fox Foundation to progress its Parkinson's program and has also announced a £16 million Series A to advance its mitochondrial therapeutics for Parkinson's and ALS.

NRG Therapeutics

Company Details